Información del artículo
RESUMEN
En este artículo se revisa la importancia de la hipertensión arterial sistólica (HSA) en el anciano. Dada su elevada prevalencia, su papel como factor de riesgo cardiovascular y la posibilidad documentada de revertir ese riesgo, se comentan los pilares de su tratamiento. Se hace especial énfasis en las posibilidades farmacológicas, presentes y futuras y en las cifras óptimas de tensión arterial que deben intentarse conseguir con el tratamiento.
Palabras clave:
Hipertensión arterial
Anciano
Hipertensión arterial sistólica
SUMMARY
In this article, the importance of systolic arterial hypertension (SAH) in the elderly is reviewed. Given its elevated prevalence, its role as a cardiovascular risk factor and the documented possibility of reversing this risk, its treatment milestones are commented on. Special emphasis is given to the present and future drug possibilities and the optimal values for blood pressure that should be aimed at with the treatment.
Key words:
Arterial hypertension
Elderly Systolic arterial hypertension
El Texto completo está disponible en PDF
Bibliografía
[1.]
Sociedad Española de Geriatría y Gerontología.
Geriatría XXI. Análisis de necesidades y recursos.
[2.]
Joint National Committee on Detection, Evaluation and treatment of High Blood Pressure.
Fifth Report of the Joint National Committee on Detection, Evaluation and treatment of High Blood Pressure. (JNC-V).
Arch Intern Med, 153 (1993), pp. 154-183
[3.]
Joint National Committee on Detection, Evaluation and treatment of High Blood Pressure.
The Sixth Report of the Joint National Committee on Detection, Evaluation and treatment of High Blood Pressure.
Arch Intern Med, 157 (1997), pp. 2413-2446
[4.]
WHO-ISH.
Guidelines for the management of hypertension J Hypertension, 17 (1999), pp. 151-183
[5.]
ECEHA.
Estudio Cooperativo Español sobre Hipertensión Arterial en el Anciano. Sociedades Españolas de Geriatría y Gerontología, Cardiología, Medicina Familiar y Comunitaria y Liga para la Lucha contra la Hipertensión Arterial.
[6.]
V.L. Burt, J.A. Culler, M. Higgings, et al.
Trends in the prevalence, awareness, treatment and control of hypertension in the adult US population. Data from the National Health and Nutrition Examination Survey (NHANES) 1960 to 1991.
Hypertension, 26 (1995), pp. 60-69
[7.]
National High Blood Pressure Education Program Working Group Report on Hypertension in the Elderly.
Hypertension, 23 (1994), pp. 275-285
[8.]
J. Staessen, A. Amery, R. Fagard.
Isolated Systolic Hypertension in the Elderly.
J Hypertension, 8 (1990), pp. 393-405
[9.]
M.J. Belza, J. Quiroga, F. Beland, V. Zunzunegui.
La hipertensión en las personas mayores ancianas. Prevalencia, conocimiento, tratamiento y control.
Atenc Primaria, 19 (1997), pp. 367-371
[10.]
W.B. Kannel.
Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation for cardiovascular risk profile.
Am Hearth J, 138 (1999), pp. 205-210
[11.]
G. Leonetti, C. Cuspide, M. Facchini, M. Sramba.
Is systolic pressure better target for antihipertensive treatment than diastolic pressure?.
J Hyperten, (2000), pp. 13-20
[12.]
C.U. Chae, M.A. Pfeiffer, R.J. Glyn, G.F. Mitchell, J.Q. Taylor, C.H. Hennekens.
Increase pulse pressure and risk of heart failure in the elderly.
JAMA, 281 (1999), pp. 634-639
[13.]
M.J. Domanski, D.R. Davis, M.A. Pfeiffer, M. Kastantin, G.F. Mitchel.
Isolated Systolic Hypertension: prognostic information provided for pulse pressure.
Hypertension, 34 (1999), pp. 375-380
[14.]
J. He, P.K. Whelton.
Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiological studies and randomised controlled trials.
Am Heart J, 138 (1999), pp. 211-219
[15.]
F. Guillén Llera.
Tratamiento de la Hipertensión Arterial en el Anciano.
Rev Lat Cardiol, 18 (1997), pp. 57-62
[16.]
B. Dahlof, L.H. Lindholm, L. Hanson, et al.
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension).
Lancet, 338 (1991), pp. 1281-1285
[17.]
A. Amery, W. Birkenhager, P. Brixco, et al.
Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial.
Lancet, 2 (1985), pp. 1349-1354
[18.]
SHEP Co-operative Research Group.
Prevention of Stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results on the systolic hypertension. in the elderly program (SHEP).
JAMA, 265 (1991), pp. 3255-3264
[19.]
J.A. Staessen, R. Fagaard, L. Thijs, et al.
Morbidity and mortality in the placebo controlled European Trial on Isolated Systolic Hypertension in the Elderly (SYSTEUR).
Lancet, 360 (1997), pp. 757-764
[20.]
J.A. Staessen, J. Gorowsky, G.J. Wang, L. This, D. Dend Hond, et al.
Risk on untreated and treated Systolic Hypertension in the elderly: meta-anlysis of outcome trials.
Lancet, 355 (2000), pp. 865-872
[21.]
F. Gueyffier, C. Bulpitt, J.P. Boissel, E. Schron, T. Ekbom, R. Fagard, et al.
INDANA Group. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials.
Lancet, 353 (1999), pp. 793-796
[22.]
A. Coca Payeras.
Evolución del control de la Hipertensión Arterial en España. Resultados del estudio Controlpres-98.
Hipertensión, 15 (1998), pp. 296-307
[23.]
Ministerio de Sanidad y Consumo.
Consenso para el control de la Hipertensión Arterial en España 1996.
[24.]
M.J. Brown, C.R. Palmer, A. Castaigne, P.W. LeuW, G. Mancia, T. Rosenthal, L.M. Ruilope.
Morbidity and mortality in-patients randomised to double - blind treatment with a long-acting calcium-chanel blocker or diuretic in the International Nifedipine GTS study: Intervention as Goal in Hypertension Treatment (INSIGHT).
Lancet, 356 (2000), pp. 366-372
[25.]
L. Hansson, T. Hedner, P. Lund-Johansen, S.E. Kjheldsen, L.H. Lindholm, et al.
Randomised trial of effects of calcium antagonist compared with diuretics and B-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazen (NORDIL) study.
Lancet, 356 (2000), pp. 359-364
[26.]
D.P. Brooks, R.R. Ruffolo.
Pharmacological mechanism of angiotensina II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
J Hypertens, 2 (1999), pp. 27-32
[27.]
G.L. Plosker, R.H. Foster.
Eprosartan: a review of its use in the management of hypertension.
Drugs, 60 (2000), pp. 177-201
[28.]
D.P. Brooks, E.H. Olhstein, R.R. Ruffolo.
Pharmacology of eprosartan, an anagiotensin II receptor antagonist: exploring hypotheses for clinical data.
Am Heart J, 138 (1999), pp. 246-251
[29.]
H. Krum, R.J. Viskoper, Y. Lacourciere, M. Budde, V. Charlon.
The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension.
N Engl J Med, 338 (1998), pp. 784-790
[30.]
J.C. Bulpitt Jr..
Vasopeptidasa inhibition: a new concept in blood pressure management.
J Hypertens, 17 (1999), pp. 37-43
[31.]
L.V. Franse, M. Pahor, M. Di Bari, G.W. Somer, W.C. Cushman, W.B. Applegate.
Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program.
Hypertension, 35 (2000), pp. 1025-1030
[32.]
J.A. Staessen, J.G. Wang, L. Thijs, R. Fagard.
Overview of outcome trials in older patients with isolated Systolic Hypertension.
Hypertension, 13 (1999), pp. 859-863
[33.]
L. Hansson, A. Zanchetti, S.G. Carrutrs, B. Dahlöf, D. Elmfeldt, S. Julius, et al.
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.
Lancet, 351 (1998), pp. 1755-1762
Copyright © 2001. Sociedad Española de Geriatría y Gerontología
